Comparative Effectiveness of Upadacitinib Versus Ustekinumab in Ulcerative Colitis Patients With Prior Tumor Necrosis Factor Inhibitor Exposure

In patients with ulcerative colitis and prior anti-TNF exposure, upadacitinib was associated with lower oral corticosteroid use than ustekinumab over 1 year, with no significant differences in rates of colectomy, ED visits or hospitalizations. These findings suggest a potanial higher effectiveness of upadacitinib compared with ustekinumab and may help inform treatment selection in this population.